SCHEMBL12331

SCHEMBL12331

Cc1noc2ccccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA3 P07451 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
MAOB P27338 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA13 Q8N1Q1 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
FAAH O00519 1/20 0.43
MGLL Q99685 1/20 0.43
BRD4 O60885 3/20 0.42
BRD2 P25440 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5918772 0.98 LMNA (0.43) LMNACA12CA1CA2CA3
Benzenesulfonamide SCHEMBL6989482 0.82 CA2 (0.52) LMNACA12CA1CA2CA3
Benzenesulfonamide SCHEMBL9273975 0.78 BRD4 (0.46) LMNACA12CA1CA2CA3
SCHEMBL20870956 0.74 GAA (0.47) LMNABRD4BRD2EPHX2NPC1
SCHEMBL24950250 0.74 BRD4 (0.47) BRD4BRD2EPHX2CYP2A6CHRNB2
SCHEMBL4930668 0.73 CA12 (0.46) LMNACA12CA1CA2CA3
SCHEMBL8103815 0.73 CA12 (0.46) LMNACA12CA1CA2CA3
SCHEMBL6585306 0.73 KCNA3 (0.42) BRD4BRD2CYP2A6CYP3A4TDO2
SCHEMBL4399692 0.73 CHRNB2 (0.45) MAOBESR1ESR2BRD4KDM4E
SCHEMBL5985206 0.73 MAPT (0.53) LMNABRD4NPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 601 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 US claimed
WO-2007001335-A2 RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-01-04 WO claimed
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. (US) 2006-09-21 US claimed
EP-1430037-A4 ZONISAMIDE INTERMEDIATE AND SYNTHESIS TEVA PHARMA (IL) 2004-11-17 EP claimed
US-20040138471-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms MENDELOVICI MARIOARA (IL) 2004-07-15 US claimed
EP-1430037-A1 ZONISAMIDE INTERMEDIATE AND SYNTHESIS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2004-06-23 EP claimed
WO-2003020708-A1 ZONISAMIDE INTERMEDIATE AND SYNTHESIS TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2003-03-13 WO claimed
US-20260102395-A1 INHIBITING HISTONE DEACETYLASE 6 EIKONIZO THERAPEUTICS, INC. (US) 2026-04-16 US disclosed
US-20260062393-A1 Compounds CTXT PTY LTD (AU) 2026-03-05 US disclosed
CN-121537357-A N-tridentate methyl benzoisoxazole salt and preparation method and application thereof 中国医学科学院药用植物研究所 2026-02-17 CN disclosed
CN-121537357-A N-tridentate methyl benzoisoxazole salt and preparation method and application thereof 中国医学科学院药用植物研究所 2026-02-17 CN disclosed
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 US disclosed
US-12365655-B2 Compounds CTXT PTY LTD (AU) 2025-07-22 US disclosed
US-6255515-B1 COORDINATION POLYMERIZATION CATALYSTS MITSUBISHI CHEMICAL CORPORATION (JP) 2001-07-03 US disclosed
EP-0985674-A1 ORGANIC COMPOUNDS CONTAINING SILICON OR GERMANIUM, TRANSITION METAL COMPLEXES, CATALYST FOR $g(a)-OLEFIN POLYMERIZATION, AND PROCESSES FOR PRODUCING $g(a)-OLEFIN POLYMERS MITSUBISHI CHEMICAL CORPORATION (JP) 2000-03-15 EP disclosed
US-5750542-A Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors PFIZER (US) 1998-05-12 US disclosed
US-5538984-A Methods of using piperidyl-benzisoxazole and benisothiazole derivatives as cholinesterase inhibitors PFIZER INC. (US) 1996-07-23 US disclosed
EP-0646115-A1 HETEROCYCLIC-CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 1995-04-05 EP disclosed
US-5171891-A Using sulfur containing oxy acids and their salts ALLIED-SIGNAL INC. (US) 1992-12-15 US disclosed
WO-1992017475-A1 HETEROCYCLIC-CYCLIC AMINE DERIVATIVES PFIZER INC. (US) 1992-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138471-A1 Novel sulfonation method for zonisamide intermediate in zonisamide synthesis and their novel crystal forms CA3, ARSA, CBS LMNA 2371/4885CA12 64/4885CA1 10/4885
US-20260062393-A1 Compounds SCN2B, ABCB11, SCN1B LMNA 3274/4885CA12 906/4885CA1 1778/4885
US-20260102395-A1 INHIBITING HISTONE DEACETYLASE 6 HDAC6, HDAC1, HDAC8 LMNA 1902/4885CA12 1670/4885CA1 345/4885
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC1 LMNA 4394/4885CA12 4745/4885CA1 4868/4885
US-20060211603-A1 Ramoplanin derivatives possessing antibacterial activity CLSPN, LMAN2, RPN2 LMNA 3704/4885CA12 2695/4885CA1 3211/4885
US-12365655-B2 Compounds SLC10A1, ABCB11, PCSK9 LMNA 1392/4885CA12 365/4885CA1 881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.